WASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Non-Alcoholic Steatohepatitis (NASH) Market finds that growing demand for ideal NASH therapeutics is expediting market growth. Primarily driven by increasing pharmaceutical Research and Development (R&D) expenditure, the total global Non-Alcoholic Steatohepatitis (NASH) Market is estimated to reach USD 21,879 Million by 2028, up from USD 1,569 Million in 2021, at a Compound Annual Growth Rate (CAGR) of 60.4%.
Furthermore, the escalating obese population across the globe is also anticipated to augment the growth of the Global Non-Alcoholic Steatohepatitis (NASH) Market, states Vantage Market Research, in a report, titled “Non Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib), by Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)”.
Click Here To Access The Free Sample Report @ https://www.vantagemarketresearch.com/non-alcoholic-ateatohepatitis-nash-market-1253/request-sample
(The Free Sample Of This Report Is Readily Available On Request).
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 160+ Pages Research Report (Including latest research)
- Provide chapter-wise guidance on request 2021 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Vantage Market Research methodology.
(Please note that the sample of this report has been updated to include the COVID-19 impact study prior to delivery.)
List of Prominent Players in the Non-Alcoholic Steatohepatitis (NASH) Market:
Genfit, Allergan plc (Tobira Therapeutics, Inc.), Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galectin Therapeutics, Inc.
Market Dynamics:
Growth in Demand for Ideal NASH Therapeutics and Launch of Pipeline Drugs to Fuel Global Non-Alcoholic Steatohepatitis (NASH) Market
Population across the globe is increasing explosively. This is providing the large base of population suffering from NASH. This is increasing the demand for Non-Alcoholic Steatohepatitis (NASH) therapeutics. To meet the untapped demand and grasp the opportunity the government and several major players are investing their money heavily to improve the therapeutics, increase the production of therapeutics as well as to identify and launch the new drug for the treatment for Non-Alcoholic Steatohepatitis (NASH). Thus, owing to increasing investment and huge base of population the market is anticipated to grow over the forecast period. However, complex pathophysiology, unknown etiology, and high cost of treatment may act as restraining factor for the market growth.
Increase in Prevalence of Chronic Diseases to Stimulate the Market Growth
Since past few years, the chronic disease prevalence is increasing at its wildest level. Also, the trend is changing towards busy lifestyle is leading to increase in number of obese populations. This is owing to improper nutrition, and lack of exercise. Owing to increasing obese population, the prevalence of people suffering from high cholesterol, high triglycerides, and metabolic syndrome is increasing. Also, prevalence of people suffering from polycystic ovary syndrome, sleep apnea, and underactive thyroid is increasing. These factors are the major risk factors for Non-Alcoholic Steatohepatitis (NASH). Thus, consequently; increasing the population suffering from Non-Alcoholic Steatohepatitis (NASH) further increasing the demand for Non-Alcoholic Steatohepatitis (NASH) therapeutics, and driving the growth of the market.
Purchase This Premium Report Now @ https://www.vantagemarketresearch.com/buy-now/non-alcoholic-ateatohepatitis-nash-market-1253/1
Benefits of Purchasing Non-Alcoholic Steatohepatitis (NASH) Market Reports:
- Customer Satisfaction: Our team of experts assists you with all your research needs and optimizes your reports.
- Analyst Support: Before or after purchasing the report, ask a professional analyst to address your questions.
- Assured Quality: Focuses on accuracy and quality of reports.
- Incomparable Skills: Analysts provide in-depth insights into reports.
COVID-19 Impact Analysis:
The COVID-19 outbreak has affected various industries worldwide. Governments across the world implemented strict lockdown measures and social distancing norms in order to restrict the swift spread of the pandemic. Manufacturing facilities around the world were shut down during the initial stages of the pandemic. Moreover, the economic crisis after the pandemic might lead to a significant delay in the commercial roll-out of the healthcare industry. Hence, market players faced numerous challenges as disruptions in the supply chain were observed. However, things will improve in the second half of 2022 as more supplies will come online. The impact of COVID-19 on the market demand is considered while estimating the current and forecast market size and growth trends of the market for all the regions and countries based on the following data points:
- Impact Assessment of COVID-19 Pandemic
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Quarterly Market Revenue Forecast by Asia Pacific 2020 & 2021
- Key Strategies Undertaken by Companies to Tackle COVID-19
- Long Term Dynamics
- Short Term Dynamics
The report on Non-Alcoholic Steatohepatitis (NASH) Market highlights:
- Assessment of the market
- Premium Insights
- Competitive Landscape
- COVID Impact Analysis
- Historic Data, Estimates and Forecast
- Company Profiles
- Global and Regional Dynamics
Read Full Research Report @ https://www.vantagemarketresearch.com/industry-report/non-alcoholic-ateatohepatitis-nash-market-1253
Regional Analysis:
North America Dominates the Global Non-Alcoholic Steatohepatitis (NASH) Market
North America has dominated the Global Non-Alcoholic Steatohepatitis (NASH) Market in 2021 and is likely to continue the same trend during the forecast period. This is attributable to the improving healthcare infrastructure in economies like the India, and China in the region. Additionally, the increasing prevalence of NASH among the population owing to increasing prevalence of people suffering from high cholesterol, high triglycerides, and metabolic syndrome as well as polycystic ovary syndrome, sleep apnea, and underactive thyroid is increasing the people suffering from NASH. Consequently, boosting the growth of Non-Alcoholic Steatohepatitis (NASH) Market over the forecast period.
Recent Developments:
April 2018: AstraZeneca has licensed IONIS-AZ6-2.5-L, which has been renamed to AZD2693. The newly licensed drug is designed to inhibit an undisclosed target to treat patients with Non-Alcoholic Steatohepatitis (NASH).
Browse Summary of this Research Report: https://www.vantagemarketresearch.com/blog/non-alcoholic-steatohepatitis-nash-657837
Key questions answered in the report:
- Which regional market will show the highest and rapid growth?
- Which are the top five players of the Non-Alcoholic Steatohepatitis (NASH) Market?
- How will the Non-Alcoholic Steatohepatitis (NASH) Market change in the upcoming six years?
- Which application and product will take a lion’s share of the Non-Alcoholic Steatohepatitis (NASH) Market?
- What is the Non-Alcoholic Steatohepatitis (NASH) market drivers and restrictions?
- What will be the CAGR and size of the Non-Alcoholic Steatohepatitis (NASH) Market throughout the forecast period?
This market titled “Non-Alcoholic Steatohepatitis (NASH) Market” will cover exclusive information in terms of, Regional Analysis, Forecast, and Quantitative Data – Units, Key Market Trends, and various others as mentioned below:
| Report Attribute | Details |
| Market Size in 2021 | USD 1,569 Million |
| Projected Market Size in 2028 | USD 21,879 Million |
| CAGR Growth Rate | CAGR of 60.4% From 2022 - 2028 |
| Base Year | 2021 |
| Historic Years | 2016 - 2020 |
| Forecast Years | 2022 - 2028 |
| Segments Covered | Drug Type
|
| Quantitative Data - Units | Revenue in USD Million/Billion and CAGR from 2022 to 2028 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
| Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
| Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization of the Report:
The report can be customized as per client needs or requirements. For any queries, you can contact us on sales@vantagemarketresearch.com or +1 (202) 380-9727. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.
Download Free Sample Report Now @ https://www.vantagemarketresearch.com/non-alcoholic-ateatohepatitis-nash-market-1253/request-sample
Browse More Related Report:
- Autologous Cell Therapy Product Market:- https://www.vantagemarketresearch.com/industry-report/autologous-cell-therapy-product-market-1298
- Single Cell Analysis Market:- https://www.vantagemarketresearch.com/industry-report/single-cell-analysis-market-1295
- 3D Cell Culture Market:- https://www.vantagemarketresearch.com/industry-report/3d-cell-culture-market-1286
- Genomics in Cancer Care Market:- https://www.vantagemarketresearch.com/industry-report/genomics-in-cancer-care-market-1285
About Vantage Market Research:
Vantage Market Research is a reputed company committed to providing high quality data and market research services. The company provides quantified B2B high quality research on more than 20,000 emerging markets. The company offers detailed reports on multiple industries including chemical materials and energy, food and beverages, healthcare, technology, etc. The company comprises over 125 analysts and consultants, adding more than 1,100 market research reports to its vast database every year. The company’s clientele base spans across 70% of the Global Fortune 500 companies.
Follow Us on LinkedIn: https://www.linkedin.com/company/vantage-market-research/
Follow Us on Twitter: https://twitter.com/vantagemarketr
Contact us
Eric Kunz
6218 Georgia Avenue NW Ste 1 - 564
Washington DC 20011-5125
United States Tel: +1 202 380 9727
Email: sales@vantagemarketresearch.com
Website: https://www.vantagemarketresearch.com/
Latest Vantage Market Research Press Releases @ https://www.vantagemarketresearch.com/insight/press-releases
Latest Vantage Market Research Blog @ https://www.vantagemarketresearch.com/insight/blogs
Blog:
- https://bwsc.kr/
- https://makitirapide.com/
- https://www.globalresearchwire.com/
- https://marketstrades.com/
- https://v-mr.biz/
